Ambrx's Partnership

Ambrx raised a round of funding on September 23, 2011. Investors include Bristol-Myers Squibb.

Ambrx is a clinical-stage biotechnology company focused on discovering and developing first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates. The company's proprietary…

Articles about Ambrx's Partnership: